Fed. Circ. Won't Restore Allergan's Restasis Patent Claims
The Federal Circuit on Tuesday declined to restore invalidated patent claims for Allergan Inc.'s dry-eye drug Restasis, delivering a fresh boost to proposed generics of the blockbuster eye-drop medicine....To view the full article, register now.
Already a subscriber? Click here to view full article